Cilofexor
Phase 1Completed 0 watching 0 views this week💤 Quiet
32
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Nonalcoholic Steatohepatitis (NASH)
Conditions
Nonalcoholic Steatohepatitis (NASH), Primary Sclerosing Cholangitis (PSC)
Trial Timeline
Jul 13, 2016 → Oct 16, 2018
NCT ID
NCT02808312About Cilofexor
Cilofexor is a phase 1 stage product being developed by Gilead Sciences for Nonalcoholic Steatohepatitis (NASH). The current trial status is completed. This product is registered under clinical trial identifier NCT02808312. Target conditions include Nonalcoholic Steatohepatitis (NASH), Primary Sclerosing Cholangitis (PSC).
Hype Score Breakdown
Clinical
10
Activity
5
Company
9
Novelty
3
Community
2
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04060147 | Phase 1 | Terminated |
| NCT02808312 | Phase 1 | Completed |
Competing Products
20 competing products in Nonalcoholic Steatohepatitis (NASH)